*Note: This page contains materials in the Portable Document Format (PDF). The free Adobe Reader may be required to view these files.
March 7, 2014—We are pleased to share this VIS update news with our immunization partners. The pediatric Multi-Vaccine VIS is being temporarily removed from service so it can be updated to reflect current ACIP recommendations. An updated edition should be available by mid-2014. Do Not Use 11/16/12 edition of the Multi-Vaccine VIS. Use the individual VISs when DTaP, Hib, Hepatitis B, Polio, PCV13 and/or Rotavirus vaccines are administered. By federal law, all vaccine providers must give patients, or their parents or legal representatives, the appropriate Vaccine Information Statement (VIS) whenever a vaccination is given.
Two-Dose Varicella Vaccination Coverage Among Children Aged 7 years–Six Sentinel Sites, United States, 2006–2012
February 28, 2014—We are pleased to share the following articles with our immunization partners. The Centers for Disease Control and Prevention (CDC) features articles on vaccinations in the Morbidity and Mortality Weekly Report (MMWR) Volume 63, No. RR-1 and No.8, February 28, 2014. This report is available at www.cdc.gov/mmwr/.
Haemophilus influenzae–This report compiles and summarizes all recommendations from CDC's ACIP regarding prevention and control of Haemophilus influenzae type b (Hib) disease in the United States.
This report does not contain any new recommendations; it is intended for use by clinicians, public health officials, vaccination providers, and immunization program personnel as a resource. ACIP recommends routine vaccination with a licensed conjugate Hib vaccine for infants aged 2 through 6 months (2 or 3 doses, depending on vaccine product) with a booster dose at age 12 through 15 months. ACIP also recommends vaccination for certain persons at increased risk for Hib disease (i.e., persons who have early component complement deficiencies, immunoglobulin deficiency, anatomic or functional asplenia, or HIV infection; recipients of hematopoietic stem cell transplant; and recipients of chemotherapy or radiation therapy for malignant neoplasms). This report summarizes current information on Hib epidemiology in the United States and describes Hib vaccines licensed for use in the United States. Guidelines for antimicrobial chemoprophylaxis of contacts of persons with Hib disease also are provided.
Two-Dose Varicella–In 2007, the ACIP recommended a routine second dose of varicella vaccine for children at age 4–6 years. Data on the number of states with 1-dose and 2-dose varicella vaccine elementary school entry requirements at the start of the school year were obtained from state immunization websites for 2007 and 2012. By 2012, thirty-six states require two doses of varicella vaccine for school entry.
February 28, 2014—We are pleased to share the Adult Immunization Standards of Practice published in the February 20th Public Health Reports with our immunization partners. The Standards lay out the roles and responsibilities of major stakeholders involved in vaccinating adults. The Association of Immunization Managers (AIM) supports the Adult Immunization Standards of Practice. Also, attached is the Morbidity and Mortality Weekly Report, volume 63, number 5, titled Noninfluenza Vaccination Coverage Among Adults—United States, 2012, documenting adult immunization coverage levels.
Research shows that adult patients are willing to get a vaccine when it is recommended by their provider. We encourage you to adopt the Adult Immunization Standards of Practice in your own practice to increase uptake of adult vaccines.
The Adult Immunization Standards of Practice guidance document describes the four steps that every provider should take to encourage their adult patients to get vaccinated:
February 25, 2014—We are pleased to share the following training event with our immunization partners. Please see the flyer below for event detail.
On March 13th, the Palm Beach County Childhood and Adult Coalition will present "Vaccines: Protect, Promote, Prevent." The event will take place Thursday, March 13, 2013 at the Bethesda Memorial Hospital Conference Room, 2815 South Seacrest Boulevard, Boynton Beach, from 5:30–8:30 pm. CEUs and CMEs are offered for this event. RSVP by Thursday, March 6, 2014 by calling 561-840-4568.
February 11, 2014—We are pleased to share this VIS update news with our immunization partners.
An updated VIS for Hib (Haemophilus Influenzae type b) and Td (Tetanus, Diphtheria) were posted at www.cdc.gov/vaccines/hcp/vis/index.html on February 4, 2014. Because both VISs contain a change in the adverse events section, the new VIS should be used beginning immediately. An accompanying Provider Information Sheet will be posted soon. By federal law, all vaccine providers must give patients, or their parents or legal representatives, the appropriate Vaccine Information Statement (VIS) whenever a vaccination is given.
Users of the Florida SHOTS immunization registry will automatically access this updated VIS when they print VIS from within the system.
February 7, 2014—We are pleased to share the following article with our immunization partners. The Centers for Disease Control and Prevention (CDC) features an article on adult vaccinations in the Morbidity and Mortality Weekly Report (MMWR) Volume 63, No.5, February 7, 2014. This report is available at www.cdc.gov/mmwr/.
Vaccinations are recommended throughout life to prevent vaccine-preventable diseases and their sequelae. Adult vaccination coverage, however, remains low for most routinely recommended vaccines and well below Healthy People 2020 targets. To assess vaccination coverage among adults aged ≥19 years for selected vaccines, CDC analyzed data from the 2012 National Health Interview Survey (NHIS). This report summarizes the results of that analysis.
February 5, 2014—The deadline is fast approaching to recognize individuals for their outstanding work in improving immunization services for children. Please submit your nominees for the 2014 Childhood Immunization Champion Award to Laura Rutledge, RN by Friday, February 14, 2014.
The Centers for Disease Control and Prevention (CDC) is proud to present the Third Annual Childhood Immunization Champion Award Program. This annual award recognizes individuals who make a significant contribution toward improving public health in their communities through their work in childhood immunization. Let's take this opportunity to garner some accolades for the great immunization partners in our state. Each year, up to one CDC Immunization Champion from each of the 50 U.S. states, 8 U.S. Territories and Freely Associated States, and the District of Columbia will be honored during National Infant Immunization Week (NIIW), April 26–May 3, 2014.
The Champion Award is intended to recognize individuals who are working at the local level. It honors those who are doing an exemplary job or going above and beyond to promote or foster childhood immunizations in their communities. The nomination and selection of a local Champion should be based on meeting one or more of the following criteria:
Champions can include coalition members, parents, health care professionals (e.g., physicians, nurses, physicians’ assistants, nurse practitioners, medical assistants, etc.), and other immunization leaders who meet the award criteria. Immunization program managers, state and federal government employees of health agencies, individuals who have been affiliated with and/or employed by pharmaceutical companies and those who have already received the award are not eligible to apply. For details, see page 3 of the nomination packet [10 pages]
Please submit your nominations to Laura Rutledge, Executive Community Health Nursing Director, in our State Immunization Section by Friday, February 14, 2014.
Information and nominating forms are available on the CDC webpage at: http://www.cdc.gov/vaccines/events/niiw/champions/index.html#nominations
February 4, 2014—We are pleased to share the following MMWR publication with our immunization partners. In the February 3, 2014/63 (Early Release), the Centers for Disease Control and Prevention published the Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years — United States, 2014 and Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2014.
Each year, recommendations for routine use of vaccines in children, adolescents, and adults in the United States are developed by the Advisory Committee on Immunization Practices (ACIP). We recommend that all healthcare providers visit http://www.cdc.gov/mmwr/ to read the article for important details and changes to last year's schedules.
Changes to the Immunization Schedules for Persons Aged 0 Through 18 Years:
Changes to the Immunization Schedules for Adults aged 19 Years or Older:
January 30, 2014—The Immunization Section is pleased to share the following training opportunities from GlaxoSmithKline (GSK) and Merck Medical Forums.
Please see GSK attachment for registration requirements, speakers and times. Programs are available on the following dates:
Please see Merck attachment for registration requirements and speaker information. The program is scheduled for: February 6, 2014, 1 PM Central/2 PM Eastern.
No CMEs or CEUs are available for these programs.Note: The Immunization Section makes every attempt to provide training on a variety of subjects/issues, without endorsement, for those interested in immunizations.
January 22, 2014—The Immunization Section is pleased to share the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention webinar in preparation for National Infant Immunization Week (NIIW) 2014. NIIW is set for April 26–May 3, 2014. This year’s theme is Harnessing National Infant Immunization Week (NIIW) 2014 to Increase the Reach and Impact of Your Program Long-Term.
This webinar is scheduled for Tuesday, February 11 at 1 PM EST, the webinar will cover:
This free webinar requires pre-registration. To register, go to 2014 NIIW Webinar Registration and (Depending upon your computer, you may have to depress the CTRL key while clicking the link).
Once you are registered, you will receive a confirmation email with instructions for joining the session.
January 23, 2014—The Florida Immunization Section is pleased to share new training courses from the Centers for Disease Control and Prevention’s (CDC) You Call the Shots. You Call the Shots is an interactive, web-based immunization training course. It consists of a series of modules that discuss vaccine-preventable diseases and explains the latest recommendations for vaccine use. Each module provides learning opportunities, self-test practice questions, reference and resource materials and an extensive glossary. Modules ten and sixteen are updated and information is available below.
These free courses are available on the CDC’s Vaccine and Immunizations website at: www.cdc.gov/vaccines/ed/youcalltheshots.htm.
These courses are intended for nurses, nursing students, medical assistants, pharmacists and other health professionals who provide immunizations. Continuing education credit is available for the individual modules to physicians, nurses, health educators, and pharmacists.
Module Ten: Immunization: You Call the Shots–Storage and Handling—2014
Module Sixteen: Immunization: You Call the Shots–Vaccines for Children (VFC) Program—2014
December 20, 2013—The Immunization Section would like to share this important information with colleagues regarding reports of severe influenza illness in pregnant women.
In recent weeks, the Florida Department of Health has received reports of severe influenza illness, including hospitalizations requiring ICU care, among pregnant women. None of these pregnant women experiencing severe complications had received the 2013–2014 influenza vaccine. Via review of emergency department chief complaint data in ESSENCE-FL, the Bureau of Epidemiology has also seen an increase in recent weeks of the number of pregnant women presenting for care to emergency departments for influenza chief complaints.
Please see letter below signed by Anna Likos, MD, MPH, Director and State Epidemiologist, Division of Disease Control and Health Protection, for providers encouraging them to vaccinate pregnant women for influenza. County health department epidemiology programs have assisted in distributing this information in their communities with a special focus on the obstetrics community as well as pharmacies and other locations that administer vaccine to pregnant women.
December 20, 2013—The Immunization Section would like to make you aware of a voluntary recall of Gardasil Vaccine being communicated on December 20, 2013 by Merck to their customers via the attached letter, which provides instructions about the recall. Gardasil vaccine was distributed in both the public and private sectors.
This recall affects one lot of Gardasil vaccine (NDC 00006-4045-41; Lot # J007354). Merck is communicating with customers who received this lot number on Friday, December 20, 2013 via the attached documents, which provide instructions on the recall. If you do not receive communication from Merck, your vaccine is not involved in the recall. This voluntary recall is being conducted due to the potential for a limited number of vials in this lot to contain glass particles. Information about the details of the recall is included in the attached documents. Patients who received this lot number do not need to be revaccinated.
Distribution of this lot by CDC’s centralized distributor (McKesson Distribution Center) for the Vaccines for Children (VFC) Program occurred during the first two weeks of October 2013. VFC Program providers may review the “Transaction History” in the Florida State Health Online Tracking System (SHOTS) to determine if your office received this lot number.
Merck will be providing credit/replacement differently depending on whether the vaccine was privately purchased versus distributed through the VFC Program ordering and distribution mechanism:
Since providers will not be receiving replacement doses directly from Merck, VFC Program providers should order VFC Program vaccines their normal process to make up for any doses lost due to the recall.
Questions about this recall should be directed to Merck National Service Center: 1-800-672-6372, Select Prompt #2, then Prompt #3 (Monday to Friday 8:00 AM to 7:00 PM EST).
December 12, 2013—The Immunization Section would like to make you aware of a Meningococcal vaccine voluntary recall being communicated on December 2, 2013 by Novartis Vaccines to their customers via the attached letter, which provides instructions about the recall.
This precautionary and voluntary action is being taken following observation of higher-than-specified levels of residual moisture within the lyophilized Men A component vial of Menveo (NDC #46028-0208-01 , lot # M12115). Fortunately, this recall does not present any safety concerns or a need to revaccinate and there are no associated supply issues.
The vaccine in the recalled lot was distributed only in the private sector, and Novartis is working directly with the customers who purchased the vaccine regarding the recall.
Questions about this recall should be directed to Novartis Vaccines Customer Service at 1-877-683-4732 (select option #3).
November 21, 2013—The Immunization Section is pleased to provide an immunization update on meningococcal vaccine recommendations. This information was originally published in the Morbidity and Mortality Weekly Report (MMWR). Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (62(RR02);1–22) which was published on March 21, 2013 and is available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm?s_cid=rr6202a1_w. The Vaccines for Children (VFC) resolution is available at http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/02-13-2-hib.pdf.
ACIP recommends meningococcal vaccination for the following groups:
Two quadrivalent meningococcal polysaccharide-protein conjugate vaccines that provide protection against meningococcal serogroups A, C, W, and Y are licensed in the United States for use among persons as noted:
Quadrivalent meningococcal polysaccharide vaccine is the only vaccine licensed for use among persons aged ≥56 years.
A bivalent meningococcal polysaccharide protein conjugate vaccine that provides protection against meningococcal serogroups C and Y along with Haemophilus influenzae type b (Hib) is licensed for use in children aged 6 weeks through 18 months.
Both quadrivalent meningococcal conjugate vaccines and the bivalent meningococcal conjugate vaccine are available through the VFC Program.
There is limited supply of Hib-MenCY-TT (Menhibrix) as this vaccine should only be used for high-risk children. Refer to Table 7 in the above mentioned MMWR publication.
October 25, 2013—The Centers for Disease Control and Prevention published Surveillance of Influenza Vaccination Coverage—United States, 2007–08 Through 2011–12 Influenza Seasons—Surveillance Studies in the Morbidity and Mortality Weekly Report (MMWR) October 25, 2013 / 62(ss04):1–29. Visit http://www.cdc.gov/mmwr/ to read the entire document.
Seasonal influenza is associated with substantial morbidity and mortality in the United States. Rates for serious illness and death are higher among adults aged ≥65 years, children aged <2 years, pregnant women, and persons of any age who have medical conditions that place them at increased risk for influenza complications. The economic impact of influenza illness is substantial. Substantial improvement in annual influenza vaccination of recommended groups is needed to reduce the health effects of influenza and reach Healthy People 2020 targets.
The Immunization Section supports the Advisory Committee on Immunization Practices (ACIP) recommendation of routine annual influenza vaccination of all persons aged 6 months and older. Health care providers should recommend vaccination at every opportunity to all eligible persons. Health care providers should offer influenza vaccine as soon as it becomes available and should continue to offered it throughout the influenza season (i.e., as long as influenza viruses are circulating in the community).